{"mainPropery":{"diseaseId":10225,"diseaseName":"Multiple endocrine neoplasia type 2B","hasGardWebPage":true,"isRare":true,"websiteUrl":"https://rarediseases.info.nih.gov/diseases/10225/multiple-endocrine-neoplasia-type-2b","synonyms":["MEN 2B","Mucosal neuroma syndrome","Multiple endocrine neoplasia, type 3 (formerly)","Wagenmann-froboese syndrome"],"synonyms-with-source":[{"name":"MEN 2B"},{"name":"Mucosal neuroma syndrome"},{"name":"Multiple endocrine neoplasia, type 3 (formerly)"},{"name":"Wagenmann-froboese syndrome"}],"identifiers":[{"identifierType":"OMIM","identifierId":"162300"},{"identifierType":"ORPHANET","identifierId":"247709"},{"identifierType":"UMLS","identifierId":"C0025269"}]},"diseaseCategories":[{"diseaseTypeId":5,"diseaseTypeName":"Congenital and Genetic Diseases","source":"Orphanet"},{"diseaseTypeId":6,"diseaseTypeName":"Digestive Diseases","source":"Orphanet"},{"diseaseTypeId":8,"diseaseTypeName":"Endocrine Diseases","source":"Orphanet"},{"diseaseTypeId":28,"diseaseTypeName":"Hereditary Cancer Syndromes"},{"diseaseTypeId":14,"diseaseTypeName":"Metabolic disorders"},{"diseaseTypeId":1,"diseaseTypeName":"Rare Cancers"}],"organizations":[{"resourceID":638,"resourceName":"Association for Multiple Endocrine Neoplasia Disorders (AMEND)","abbreviation":"UK, New Zealand, and USA","address1":"The Warehouse","address2":"No 1 Draper Street","address3":"Southborough","address4":"Tunbridge Wells Kent TN4 0PG","address5":"","city":"","state":"","zip":"","country":"United Kingdom","phone":"+ 44 (0)1892 516076","tty":"","tollFree":"","fax":"","email":"info@amend.org.uk","url":"http://www.amend.org.uk","freeText":""},{"resourceID":2417,"resourceName":"American Multiple Endocrine Neoplasia Support","abbreviation":"","address1":"1027 Hampshire Drive","address2":"","address3":"","address4":"","address5":"","city":"Maryville","state":"TN","zip":"37801","country":"","phone":"865-238-5842","tty":"","tollFree":"","fax":"","email":"http://amensupport.org/contact%20us","url":"http://www.amensupport.org/","freeText":""},{"resourceID":3839,"resourceName":"Rare Cancers Australia","abbreviation":"","address1":"PO Box 440","address2":"","address3":"","address4":"","address5":"","city":"Bowral New South Wales","state":"","zip":"2576","country":"Australia","phone":"+61 2 4862 276","tty":"","tollFree":"","fax":"","email":"contact@rarecancers.org.au","url":"http://rarecancers.org.au/","freeText":""}],"resource descriptions":[{"id":7,"resourceId":10,"resourceName":"Online Mendelian Inheritance in Man (OMIM)","descriptionText":"<a href='http://www.omim.org/162300' target='_blank'>Online Mendelian Inheritance in Man (OMIM)</a> is a catalog of human genes and genetic disorders. Each entry has a summary of related medical articles. It is meant for health care professionals and researchers. OMIM is maintained by Johns Hopkins University School of Medicine.&nbsp;<br />\r\n","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"},{"id":8,"resourceId":11,"resourceName":"PubMed","descriptionText":"<a href='http://www.ncbi.nlm.nih.gov/sites/entrez?itool=omim_Detailed&DbFrom=omim&Cmd=Link&LinkName=omim_pubmed_calculated&IdsFromResult=162300' target='_blank'>PubMed</a> is a searchable database of medical literature and lists journal articles that discuss Multiple endocrine neoplasia type 2B. Click on the link to view a sample search on this topic.","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"},{"id":9,"resourceId":12,"resourceName":"ClinicalTrials.gov","descriptionText":"<a href='http://www.clinicaltrials.gov/ct2/results?cond=%22Multiple+endocrine+neoplasia+type+2B%22' target='_blank'>ClinicalTrials.gov</a> lists trials that are related to Multiple endocrine neoplasia type 2B. Click on the link to go to ClinicalTrials.gov to read descriptions of these studies. <br />\r\n<br />\r\n<em><strong>Please note:</strong>&nbsp;Studies listed on the&nbsp;ClinicalTrials.gov&nbsp;website are listed for informational purposes only; being listed does not reflect an endorsement by GARD or the NIH. We strongly recommend that you talk with a trusted healthcare provider before choosing to participate in any clinical study.</em>","resourceClassificationName":"Research","resourceClassificationSectionName":"Clinical Research Resources"},{"id":336,"resourceId":1154,"resourceName":"RareConnect","descriptionText":"<div style=\"margin-top: 0px; margin-bottom: 0px;\"><a href='https://www.rareconnect.org/en/community/multiple-endocrine-neoplasia' target='_blank'>RareConnect</a> has an online community for patients&nbsp;and families with this condition so they can connect with others and share&nbsp;their experiences living with a rare disease.&nbsp;The project is a joint collaboration between EURORDIS (European Rare Disease Organisation) and NORD (National Organization for Rare Disorders).</div>","resourceClassificationName":"Organizations","resourceClassificationSectionName":"Social Networking Websites"},{"id":1457,"resourceId":2104,"resourceName":"Genetic Services","descriptionText":"To find a medical professional who specializes in genetics, you can ask your doctor for a referral or you can search for one yourself. Online directories are provided by the <a href='http://www.acmg.net/ACMG/Genetic_Services_Directory_Search.aspx' target='_blank'>American College of Medical Genetics</a> and the&nbsp;<a href='https://www.findageneticcounselor.com/' target='_blank'>National Society of Genetic Counselors</a>. If you need additional help, <a href=\"https://rarediseases.info.nih.gov/about-gard/contact-gard\">contact a GARD Information Specialist</a>. You can also&nbsp;<a href='https://ghr.nlm.nih.gov/primer#consult' target='_blank'>learn more about genetic consultations</a>&nbsp;from Genetics Home Reference.","resourceClassificationName":"Find a Specialist","resourceClassificationSectionName":"Healthcare Resources"},{"id":1534,"resourceId":2165,"resourceName":"Orphanet","descriptionText":"<a href='http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=247709' target='_blank'>Orphanet</a> is a European reference portal for&nbsp;information on rare diseases and orphan drugs. Access to this database is free of charge.<br />\r\n","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"},{"id":2135,"resourceId":3342,"resourceName":"Monarch Initiative","descriptionText":"The <a href='https://monarchinitiative.org/disease/OMIM:162300' target='_blank'>Monarch Initiative</a> brings together data about this condition from humans and other species to help physicians and biomedical researchers. Monarch&rsquo;s tools are designed to make it easier to compare the signs and symptoms (phenotypes) of different diseases and discover common features. This initiative is a collaboration between several academic institutions across the world and is funded by the National Institutes of Health. Visit the website to explore the biology of this condition.","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"}],"overviewQuestion":{"questionId":12642,"questionText":"What is multiple endocrine neoplasia type 2B (MEN2B)?","answerText":"<strong>Multiple endocrine neoplasia type 2B (MEN2B)</strong> is a genetic disease in which one or more of the&nbsp;<a href=\"https://medlineplus.gov/endocrinesystem.html\">endocrine</a>&nbsp;glands are overactive and form a&nbsp;<a href=\"https://medlineplus.gov/ency/article/001310.htm\">tumor</a>&nbsp;(neoplasia). Common tumors that may be associated with MEN2B include&nbsp;<a href=\"https://medlineplus.gov/ency/article/000374.htm\">medullary thyroid carcinoma</a>&nbsp;(MTC) and tumors of the&nbsp;<a href=\"https://medlineplus.gov/ency/article/002219.htm\">adrenal glands</a>&nbsp;called&nbsp;<a href=\"https://medlineplus.gov/pheochromocytoma.html\">pheochromocytomas</a>. Other features of MEN2B can include having bumps on the lips, eyelids, and tongue. People with MEN2B typically have a body type with long arms, legs, and fingers. They may also have joints that are very loose (hyperextensible).[14440]<br />\r\n<br />\r\nMEN2B is caused by a specific genetic change (<a href=\"https://ghr.nlm.nih.gov/primer/mutationsanddisorders/genemutation\">mutation</a>&nbsp;or pathogenic variant) in the&nbsp;<a href=\"https://ghr.nlm.nih.gov/gene/RET\"><em>RET</em></a>&nbsp;<a href=\"https://ghr.nlm.nih.gov/primer/basics/gene\">gene</a>. The disease is inherited in an&nbsp;<a href=\"https://medlineplus.gov/ency/article/002049.htm\">autosomal dominant</a>&nbsp;manner. A diagnosis of MEN2B is suspected when a person has a personal or family history of medullary thyroid cancer, pheochromocytoma, or physical findings suggestive of MEN2B. The diagnosis can be confirmed with&nbsp;<a href=\"https://ghr.nlm.nih.gov/primer/testing/genetictesting\">genetic testing</a>. Treatment for MEN2B typically includes removal of the&nbsp;<a href=\"https://www.thyroid.org/thyroid-information/\">thyroid</a>&nbsp;and screening for the development of additional tumors.[14441]<br />\r\n<br />\r\nThere is another type of&nbsp;<a href=\"https://rarediseases.info.nih.gov/diseases/3830/multiple-endocrine-neoplasia-type-2\">multiple endocrine neoplasia type 2</a>&nbsp;that causes an increased risk for medullary thyroid carcinoma and pheochromocytomas. This disease is known as&nbsp;<a href=\"https://rarediseases.info.nih.gov/diseases/4881/multiple-endocrine-neoplasia-type-2a\">multiple endocrine neoplasia type 2A (MEN2A).</a>","dateModified":"2018-03-08T10:08:00"},"basicQuestions":[{"questionId":12643,"questionText":"What are the signs and symptoms of multiple endocrine neoplasia type 2B (MEN2B)?","answerText":"The signs and symptoms of multiple endocrine neoplasia type 2B (MEN2B) include the development of&nbsp;<a href=\"https://medlineplus.gov/ency/article/001310.htm\">tumors</a>&nbsp;(neoplasias) of the&nbsp;<a href=\"https://medlineplus.gov/endocrinesystem.html\">endocrine</a>&nbsp;glands. Endocrine glands are located throughout the body and are responsible for secreting&nbsp;<a href=\"https://medlineplus.gov/hormones.html\">hormones</a>. The most common tumors that are found in people with MEN2B are&nbsp;<a href=\"https://medlineplus.gov/ency/article/000374.htm\">medullary thyroid carcinoma</a>&nbsp;(MTC) and tumors of the&nbsp;<a href=\"https://medlineplus.gov/ency/article/002219.htm\">adrenal glands</a>&nbsp;called&nbsp;<a href=\"https://medlineplus.gov/pheochromocytoma.html\">pheochromocytomas</a>. MTC is a type of thyroid cancer. In addition, tumor cells from medullary thyroid carcinomas can spread (metastasize) to other parts of the body. The risk for a person with MEN2B to develop a medullary thyroid carcinoma or changes in the production of the cells of the thyroid gland (<a href=\"https://medlineplus.gov/ency/article/003441.htm\">hyperplasia</a>) is nearly 100%. People with MEN2B are most likely to develop medullary thyroid carcinomas in childhood or early adulthood.[14441]&nbsp;<br />\r\n<br />\r\nPheochromocytomas are typically not cancerous (they are usually benign), but they can cause other health problems such as high blood pressure (<a href=\"https://medlineplus.gov/highbloodpressure.html\">hypertension</a>). The risk for a person with MEN2B to develop a pheochromocytoma is about 50%.[14441]&nbsp;<br />\r\n<br />\r\nMEN2B can also cause changes in the skin. People with MEN2B may have lumps and bumps on the lips, eyelids, and tongue. They also may have eyelids and lips that appear thicker than in most people. Children with MEN2B may not have tears when they cry.[14442] Some people with MEN2B have growths that can form in the&nbsp;<a href=\"https://medlineplus.gov/ency/imagepages/9790.htm\">gastrointestinal tract</a>&nbsp;called&nbsp;<a href=\"https://medlineplus.gov/ency/article/001437.htm\">ganglioneuromas</a>. These growths can cause signs and symptoms including&nbsp;<a href=\"https://medlineplus.gov/diarrhea.html\">diarrhea</a>&nbsp;or&nbsp;<a href=\"https://medlineplus.gov/constipation.html\">constipation</a>&nbsp;and may present as early as infancy.[14443] People with MEN2B are often tall and may have long fingers, toes, arms, and legs (marfanoid habitus). They may have hyperflexible joints, especially during childhood.[14440][14441]","dateModified":"2018-03-08T10:12:00","resourceClassificationName":"Symptoms","references":[{"referenceId":14440,"authors":"Brandi ML","articleTitle":"Multiple endocrine neoplasia type 2B","bookWebsiteJournalTitle":"Orphanet","date":"April 2015","volume":"","pages":"","url":"http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=247709","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":14441,"authors":"Hughes MS, Feliberti E, Perry RR, and Vinik A","articleTitle":"Multiple Endocrine Neoplasia Type 2A (including Familial Medullary Carcinoma) and Type 2B","bookWebsiteJournalTitle":"Endotext","date":"October 8, 2017","volume":"","pages":"","url":"https://www.ncbi.nlm.nih.gov/books/NBK481898/","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":14442,"authors":"Lee R, Hyer J, Chowdhury H, and Teimory M","articleTitle":"Ocular signs of multiple endocrine neoplasia type 2B (MEN2B)","bookWebsiteJournalTitle":"The Journal of Clinical Endocrinology and Metabolism","date":"March 2012","volume":"97(3)","pages":"725-726","url":"https://www.ncbi.nlm.nih.gov/pubmed/22238409","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":14443,"authors":"","articleTitle":"Multiple Endocrine Neoplasia, Type IIB; MEN2B","bookWebsiteJournalTitle":"Online Mendelian Inheritance in Man","date":"October 13, 2016","volume":"","pages":"","url":"https://www.omim.org/entry/162300","authors2":"","placeOfPublication":"","publisher":""}]},{"questionId":12644,"questionText":"What causes multiple endocrine neoplasia type 2B (MEN2B)?","answerText":"Multiple endocrine neoplasia type 2B (MEN2B) is caused by certain genetic changes (<a href=\"https://ghr.nlm.nih.gov/primer/mutationsanddisorders/genemutation\">mutations</a>&nbsp;or pathogenic variants) in the&nbsp;<a href=\"https://ghr.nlm.nih.gov/gene/RET\"><em>RET</em></a>&nbsp;<a href=\"https://ghr.nlm.nih.gov/primer/basics/gene\">gene</a>. This gene provides instructions to the body to make a protein that helps regulate the growth and division of cells of the&nbsp;<a href=\"https://medlineplus.gov/endocrinesystem.html\">endocrine</a>&nbsp;system. This protein is supposed to tell the body when it is appropriate to allow the cells of the endocrine system to divide. When there is a pathogenic variant in the&nbsp;<em>RET</em>&nbsp;gene, the cells of the endocrine system are able to grow and divide out of control. This causes the signs and symptoms of MEN2B, as well as the increased risk for the development of&nbsp;<a href=\"https://medlineplus.gov/ency/article/001310.htm\">tumors</a>.[14441]<br />\r\n<br />\r\nAbout 95% of people who have MEN2B have a pathogenic variant in one particular area of the&nbsp;<em>RET</em>&nbsp;gene known as codon 918. Genetic changes in this region of the&nbsp;<em>RET</em>&nbsp;gene are thought to cause the&nbsp;<em>RET</em>&nbsp;gene to be more highly activated than other genetic changes within the&nbsp;<em>RET&nbsp;</em>gene. This is why MEN2B causes a higher risk for tumor development at a younger age as compared to other pathogenic variants in the&nbsp;<em>RET&nbsp;</em>gene.[14441]","dateModified":"2018-03-08T10:23:00","resourceClassificationName":"Cause","references":[{"referenceId":14441,"authors":"Hughes MS, Feliberti E, Perry RR, and Vinik A","articleTitle":"Multiple Endocrine Neoplasia Type 2A (including Familial Medullary Carcinoma) and Type 2B","bookWebsiteJournalTitle":"Endotext","date":"October 8, 2017","volume":"","pages":"","url":"https://www.ncbi.nlm.nih.gov/books/NBK481898/","authors2":"","placeOfPublication":"","publisher":""}]},{"questionId":12645,"questionText":"How is multiple endocrine neoplasia type 2B (MEN2B) inherited?","answerText":"Multiple endocrine neoplasia type 2B (MEN2B) is inherited in an&nbsp;<a href=\"https://medlineplus.gov/ency/article/002049.htm\">autosomal dominant</a>&nbsp;manner.[14440]&nbsp;<span style=\"background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;\">This means that a person only needs one copy of the&nbsp;</span><a href=\"https://ghr.nlm.nih.gov/gene/RET\"><em>RET</em></a><span style=\"background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;\">&nbsp;</span><a href=\"https://ghr.nlm.nih.gov/primer/basics/gene\"><span style=\"background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;\">gene</span></a><span style=\"background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;\">&nbsp;to have a change (</span><a href=\"https://ghr.nlm.nih.gov/primer/mutationsanddisorders/genemutation\"><span style=\"background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;\">mutation</span></a><span style=\"background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;\">&nbsp;or pathogenic variant) causing MEN2B. We inherit one copy of every gene from our mother and the other from our father. When a person who has MEN2B has children, for each child there is a:</span><br />\r\n<ul>\r\n    <li>50% chance that the child will inherit the copy of the&nbsp;<em>RET</em>&nbsp;gene with a pathogenic variant, meaning he or she will have MEN2B</li>\r\n    <li>50% chance that the child will inherit the working copy of the&nbsp;<em>RET&nbsp;</em>gene, meaning he or she will not have MEN2B</li>\r\n</ul>\r\nIn some cases, people who have MEN2B are the first people to be diagnosed in the family. This may be because they inherited the genetic change from a parent, but the parent was never diagnosed with the disease. In other cases, the genetic change may be new in the person who was diagnosed with MEN2B. Genetic changes that are new in a person are called&nbsp;<em><a href=\"https://www.cancer.gov/publications/dictionaries/genetics-dictionary?cdrid=460142\" target=\"_blank\">de novo</a></em>. It is estimated that about 50% of people with MEN2B have a genetic change that is&nbsp;<em>de novo</em>.[14441]&nbsp;","dateModified":"2018-03-08T10:24:00","resourceClassificationName":"Inheritance","references":[{"referenceId":14440,"authors":"Brandi ML","articleTitle":"Multiple endocrine neoplasia type 2B","bookWebsiteJournalTitle":"Orphanet","date":"April 2015","volume":"","pages":"","url":"http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=247709","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":14441,"authors":"Hughes MS, Feliberti E, Perry RR, and Vinik A","articleTitle":"Multiple Endocrine Neoplasia Type 2A (including Familial Medullary Carcinoma) and Type 2B","bookWebsiteJournalTitle":"Endotext","date":"October 8, 2017","volume":"","pages":"","url":"https://www.ncbi.nlm.nih.gov/books/NBK481898/","authors2":"","placeOfPublication":"","publisher":""}]},{"questionId":12646,"questionText":"How is multiple endocrine neoplasia type 2B (MEN2B) diagnosed?","answerText":"Multiple endocrine neoplasia type 2B (MEN2B) is suspected&nbsp;<span style=\"background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;\">when a doctor sees a person who has a personal or family history&nbsp;</span>of&nbsp;<a href=\"https://medlineplus.gov/ency/article/000374.htm\">medullary thyroid carcinoma</a>&nbsp;or&nbsp;<a href=\"https://medlineplus.gov/pheochromocytoma.html\">pheochromocytoma</a>. The diagnosis may also be suspected based on physical features suggestive of MEN2B such as having bumps on the eyelids or lips and long arms, legs, fingers, and toes.[14441] The diagnosis of MEN2B can be confirmed with&nbsp;<a href=\"https://ghr.nlm.nih.gov/primer/testing/genetictesting\">genetic testing</a>&nbsp;of the&nbsp;<a href=\"https://ghr.nlm.nih.gov/gene/RET\"><em>RET</em></a>&nbsp;<a href=\"https://ghr.nlm.nih.gov/primer/basics/gene\">gene</a>.[14441]","dateModified":"2018-03-08T10:28:00","resourceClassificationName":"Diagnosis","references":[{"referenceId":14441,"authors":"Hughes MS, Feliberti E, Perry RR, and Vinik A","articleTitle":"Multiple Endocrine Neoplasia Type 2A (including Familial Medullary Carcinoma) and Type 2B","bookWebsiteJournalTitle":"Endotext","date":"October 8, 2017","volume":"","pages":"","url":"https://www.ncbi.nlm.nih.gov/books/NBK481898/","authors2":"","placeOfPublication":"","publisher":""}]},{"questionId":12647,"questionText":"How might multiple endocrine neoplasia type 2B (MEN2B) be treated?","answerText":"People with multiple endocrine neoplasia type 2B (MEN2B) are recommended to have their&nbsp;<a href=\"https://www.thyroid.org/thyroid-information/\">thyroid</a>&nbsp;removed (<a href=\"https://medlineplus.gov/ency/article/002933.htm\">thyroidectomy</a>) as soon as they are diagnosed. This is because the risk for&nbsp;<a href=\"https://medlineplus.gov/ency/article/000374.htm\">medullary thyroid carcinoma</a>&nbsp;is nearly 100% in people who have MEN2B, and a thyroidectomy can prevent a person from ever developing medullary thyroid carcinoma.[14441]&nbsp;<br />\r\n<br />\r\nAfter the thyroid is removed, a person with MEN2B may still have tests to make sure a medullary thyroid carcinoma did not develop and spread before the thyroid was removed.[14441] If the medullary thyroid carcinoma cannot be completely removed, there are therapies available such as&nbsp;<a href=\"https://www.cancer.gov/publications/dictionaries/cancer-terms/def/tyrosine-kinase-inhibitor\">tyrosine kinase inhibitors</a>. These therapies can slow the growth of medullary thyroid carcinomas.[14444] People who have thyroidectomies need to take medications that contain the hormones that are normally produced by the thyroid.[14441]<br />\r\n<br />\r\nPeople with MEN2B may also be recommended to have frequent tests such as analysis of the blood or urine for signs that there may be a&nbsp;<a href=\"https://medlineplus.gov/ency/article/001310.htm\">tumor</a>&nbsp;in the&nbsp;<a href=\"https://medlineplus.gov/ency/article/002219.htm\">adrenal glands</a>(<a href=\"https://medlineplus.gov/pheochromocytoma.html\">pheochromocytoma</a>). Imaging tests such as&nbsp;<a href=\"https://medlineplus.gov/ency/article/003335.htm\">MRI</a>&nbsp;or&nbsp;<a href=\"https://medlineplus.gov/ctscans.html\">CT scan</a>&nbsp;can also be used to monitor for the development of a pheochromocytoma.[14441] If a pheochromocytoma is identified, it may be removed with surgery.[14441]","dateModified":"2018-03-08T10:30:00","resourceClassificationName":"Treatment","references":[{"referenceId":14441,"authors":"Hughes MS, Feliberti E, Perry RR, and Vinik A","articleTitle":"Multiple Endocrine Neoplasia Type 2A (including Familial Medullary Carcinoma) and Type 2B","bookWebsiteJournalTitle":"Endotext","date":"October 8, 2017","volume":"","pages":"","url":"https://www.ncbi.nlm.nih.gov/books/NBK481898/","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":14444,"authors":"Grey J and Winter K","articleTitle":"Patient quality of life and prognosis in multiple endocrine neoplasia type 2","bookWebsiteJournalTitle":"Endocrine-related Cancer","date":"February 2018","volume":"25(2)","pages":"T69-T77","url":"https://www.ncbi.nlm.nih.gov/pubmed/29066504","authors2":"","placeOfPublication":"","publisher":""}]},{"questionId":12648,"questionText":"What is the long-term outlook for people affected with multiple endocrine neoplasia type 2B (MEN2B)?","answerText":"The long-term outlook for people with multiple endocrine neoplasia type 2B (MEN2B) may depend upon when a person with the disease was diagnosed. If the disease is identified early, prior to the development of a&nbsp;<a href=\"https://medlineplus.gov/ency/article/000374.htm\">medullary thyroid carcinoma</a>, the&nbsp;<a href=\"https://www.thyroid.org/thyroid-information/\">thyroid</a>&nbsp;can be removed. Because medullary thyroid cancer often metastasizes, spreading cancer to other tissues in the body, removal of the thyroid (<a href=\"https://medlineplus.gov/ency/article/002933.htm\">thyroidectomy</a>) greatly reduces the chances that a person with MEN2B develops cancer. The other types of tumors which develop in people with MEN2B are usually not cancerous (benign) and therefore do not tend to be life-threatening.[14441]&nbsp;<br />\r\n<br />\r\nIf a person is diagnosed with MEN2B after he or she has already developed medullary thyroid carcinoma, the thyroid can be removed. If the cells of the tumor have already spread to other parts of the body (<a href=\"https://www.cancer.gov/publications/dictionaries/cancer-terms/def/metastasize\">metastasized</a>), surgery may not be able to remove all of the cancer. This can increase the risk for a person to pass away from the disease.[14441]&nbsp;<br />\r\n<br />\r\nOther symptoms of MEN2B, such as gastrointestinal symptoms, are not life-threatening but can impact a person&rsquo;s quality of life.[14444]","dateModified":"2018-03-08T10:34:00","resourceClassificationName":"Prognosis","references":[{"referenceId":14441,"authors":"Hughes MS, Feliberti E, Perry RR, and Vinik A","articleTitle":"Multiple Endocrine Neoplasia Type 2A (including Familial Medullary Carcinoma) and Type 2B","bookWebsiteJournalTitle":"Endotext","date":"October 8, 2017","volume":"","pages":"","url":"https://www.ncbi.nlm.nih.gov/books/NBK481898/","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":14444,"authors":"Grey J and Winter K","articleTitle":"Patient quality of life and prognosis in multiple endocrine neoplasia type 2","bookWebsiteJournalTitle":"Endocrine-related Cancer","date":"February 2018","volume":"25(2)","pages":"T69-T77","url":"https://www.ncbi.nlm.nih.gov/pubmed/29066504","authors2":"","placeOfPublication":"","publisher":""}]}],"references":[],"relatedDiseases":[],"gardCases":[],"news":[{"newsId":671,"dateCreated":"2020-05-20T13:39:00","publishDate":"2020-05-22T00:00:00","title":"NIH-Supported Research Survey to Examine Impact of COVID-19 on Rare Diseases Community","description":"The NIH-funded Rare Diseases Clinical Research Network (RDCRN) has launched an <a href=\"https://www.rarediseasesnetwork.org/COVIDsurvey \" target=\"_blank\">online research survey</a> to find out how the COVID-19 pandemic is impacting individuals with rare diseases, their families and their caregivers. Your participation can help the rare disease research community shed light on the needs of people with rare diseases during this and other potential health crises, in addition to informing future research efforts. The survey must be completed by December 15, 2020.","url":"https://www.rarediseasesnetwork.org/COVIDsurvey","lastModified":"2020-11-30T14:44:00","isFeatured":false}],"conferences":[],"phenoTypes":[{"phenoTypeId":11214,"phenoTypeName":"Aganglionic megacolon","percentRanges":"-"},{"phenoTypeId":6539,"phenoTypeName":"Autosomal dominant inheritance","percentRanges":"-"},{"phenoTypeId":11215,"phenoTypeName":"Colonic diverticula","percentRanges":"-"},{"phenoTypeId":13409,"phenoTypeName":"Constipation","percentRanges":"-"},{"phenoTypeId":13401,"phenoTypeName":"Diarrhea","percentRanges":"-"},{"phenoTypeId":4084,"phenoTypeName":"Disproportionate tall stature","percentRanges":"-"},{"phenoTypeId":13604,"phenoTypeName":"Elevated calcitonin","percentRanges":"-"},{"phenoTypeId":12798,"phenoTypeName":"Elevated urinary epinephrine","percentRanges":"-"},{"phenoTypeId":4090,"phenoTypeName":"Failure to thrive in infancy","percentRanges":"-"},{"phenoTypeId":699,"phenoTypeName":"Flushing","percentRanges":"-"},{"phenoTypeId":8877,"phenoTypeName":"Ganglioneuroma","percentRanges":"-"},{"phenoTypeId":9384,"phenoTypeName":"Generalized hypotonia","percentRanges":"-"},{"phenoTypeId":8723,"phenoTypeName":"Global developmental delay","percentRanges":"-"},{"phenoTypeId":14212,"phenoTypeName":"High palate","percentRanges":"-"},{"phenoTypeId":10656,"phenoTypeName":"High, narrow palate","percentRanges":"-"},{"phenoTypeId":10993,"phenoTypeName":"Hyperlordosis","percentRanges":"-"},{"phenoTypeId":5688,"phenoTypeName":"Joint laxity","percentRanges":"-"},{"phenoTypeId":7902,"phenoTypeName":"Kyphosis","percentRanges":"-"},{"phenoTypeId":7802,"phenoTypeName":"Medullary thyroid carcinoma","percentRanges":"-"},{"phenoTypeId":8716,"phenoTypeName":"Muscular hypotonia","percentRanges":"-"},{"phenoTypeId":14500,"phenoTypeName":"Myopathy","percentRanges":"-"},{"phenoTypeId":3515,"phenoTypeName":"Nodular goiter","percentRanges":"-"},{"phenoTypeId":1382,"phenoTypeName":"Parathyroid hyperplasia","percentRanges":"-"},{"phenoTypeId":14151,"phenoTypeName":"Pectus excavatum","percentRanges":"-"},{"phenoTypeId":3896,"phenoTypeName":"Pes cavus","percentRanges":"-"},{"phenoTypeId":13292,"phenoTypeName":"Pheochromocytoma","percentRanges":"-"},{"phenoTypeId":5810,"phenoTypeName":"Proximal femoral epiphysiolysis","percentRanges":"-"},{"phenoTypeId":13814,"phenoTypeName":"Scoliosis","percentRanges":"-"},{"phenoTypeId":9164,"phenoTypeName":"Thick eyebrow","percentRanges":"-"},{"phenoTypeId":9781,"phenoTypeName":"Thick lower lip vermilion","percentRanges":"-"}],"medicalProducts":[],"EncodedName":"Multiple_endocrine_neoplasia_type_2B"}